The UK and US have concluded a major commercial pact that will preserve zero levies on UK medicine exports going into the American market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has pledged to boost spending on pharmaceuticals through the National Health Service (NHS). This move secures that duties on these key exports will be held at zero for a period of three years.
This agreement is in response to previous warnings to dramatically increase import taxes on patented drug imports, with increases mentioned up to double the cost.
"This deal with the United Kingdom bolsters the worldwide climate for cutting-edge drugs and brings much-needed balance to American-British pharmaceutical trade," a release declared.
Commercial Impact
Medicines constitute one of the the United Kingdom's most significant export categories to the US, which is by far the largest market for major British pharmaceutical firms.
Trade data show that in the 12 months prior to last September, the UK exported pharmaceutical products worth £11.1bn to the US. This value made up nearly one-fifth of total UK exports in that period.
"This agreement safeguards jobs, stimulates funding and facilitates the UK to establish itself as a global hub for medical research," the Business and Trade Secretary stated.
Key NHS Changes
The agreement involves several notable changes from the UK:
- Higher Cost Ceiling: The UK will increase the price threshold at which it judges new therapies to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a goal to increase total NHS spending on drugs from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The amount drug companies must return to the NHS to stay within budget will be restricted at fifteen percent. Last year, repayments were more than twenty percent.
Recent Tensions
The deal follows a ongoing row between the pharmaceutical industry and the ministers over medicine costs and approval rates.
This friction were intensified by claims that US patients were charged several times more for the same drugs than people in the Britain and the EU.
Over the last 18 months, several significant drug company projects in the UK have been delayed or abandoned, while substantial expansions have been pledged toward projects in the United States.
A senior figure acknowledged that the NHS needed to increase expenditure on medicines, noting that its spending on drugs had shrunk as a proportion of its resources over the last ten years.
